SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Lorraine Hansberry

PatientLorraine Hansberry
Date of birth1993-05-19
IdentifiersMRN HR-ML034-SYN; SSN (made up) 000-34-7158
Document date2026-10-05
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review six weeks after pancreaticoduodenectomy: pathology, diabetes, digestion, and the plan for chemotherapy after surgery. [S]

History of Present Illness

Ms. Hansberry returns six weeks after a pylorus-preserving pancreaticoduodenectomy with resection of a segment of the superior mesenteric vein. She was in hospital nine days; her stomach was slow to empty for the first week and then recovered. Insulin glargine was started four days after surgery when her glucose rose, and her home fasting readings are now 140 to 170 mg/dL on 8 units. She finished four weeks of enoxaparin two weeks ago. Since surgery her stools have been loose and pale after larger meals despite pancrelipase. She has lost 2.4 kg since surgery. Pain is 2 out of 10 at the wound and she rarely needs oxycodone. She is writing again for an hour each morning. Fingertip tingling is barely there. She saw Dr. Adeyemi-Rourke last week, who recommends chemotherapy after surgery starting next week. She has had no thoughts of self-harm. [S]

ElementDetail
OperationPylorus-preserving pancreaticoduodenectomy with vein resection; nine days in hospital; delayed gastric emptying resolved
PathologyypT2N1: 2.3 cm residual adenocarcinoma, 2 of 18 nodes, perineural invasion; all margins clear (R0); partial treatment response
DiabetesInsulin glargine 8 units since day 4; fasting 140 to 170 mg/dL
DigestionLoose, pale stools after larger meals; weight down 2.4 kg since surgery
Plan proposedSix cycles of fluorouracil, leucovorin and irinotecan, without oxaliplatin, starting next week

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired in the afternoons; weight 51.8 kg; no fever
GastrointestinalPositiveLoose, pale stools after larger meals; eating five small meals; no vomiting
EndocrinePositiveFasting glucose 140 to 170 mg/dL; no low readings
NeurologicalNegativeFingertip tingling barely present
CardiovascularNegativeNo leg swelling or calf pain
PsychiatricPositiveRelieved about the margins, worried about the lymph nodes; PHQ-9 7, GAD-7 6; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route2026-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route2026-04-24 to 2026-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route2026-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route2026-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route2026-05-04 to 2026-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route2026-05-18 to 2026-07-13completedS
Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6Day 1 of cycle 6Intravenous route2026-07-27 to 2026-07-27completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route2026-05-20 to 2026-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route2026-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route2026-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route2026-06-29 to 2026-08-21completedS
Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days40 mEq today, then 20 mEq daily for three daysOral route2026-07-16 to 2026-07-19completedS
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg once daily for 28 daysSubcutaneous route2026-08-24 to 2026-09-21completedS
Insulin glargine 100 units/mL pen, 8 units under the skin at night8 units at nightSubcutaneous route2026-08-28 to 2026-10-05completedS
Insulin glargine 100 units/mL pen, 10 units under the skin at night10 units at nightSubcutaneous route2026-10-05activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snackThree capsules with each meal, two with each snackOral route2026-10-05activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-05Body height163cmS
2026-10-05Body weight51.8kgS
2026-10-05Body mass index (BMI) [Ratio]19.5kg/m2S
2026-10-05Systolic blood pressure106mm[Hg]S
2026-10-05Diastolic blood pressure68mm[Hg]S
2026-10-05Heart rate86/minS
2026-10-05Respiratory rate16/minS
2026-10-05Body temperature36.7CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-05Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
2026-10-05Leukocytes [#/volume] in Blood by Automated count8.210*3/uL4-11 10*3/uLNormalS
2026-10-05Neutrophils [#/volume] in Blood by Automated count5.110*3/uL1.5-7.7 10*3/uLNormalS
2026-10-05Platelets [#/volume] in Blood by Automated count30210*3/uL150-400 10*3/uLNormalS
2026-10-05Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-10-05Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-10-05Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.59-1.04 mg/dLNormalS
2026-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M116mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-05Glucose [Mass/volume] in Serum or Plasma156mg/dL70-99 mg/dLHighS
2026-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
2026-10-05Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma110U/L35-104 U/LHighS
2026-10-05Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-10-05Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
2026-10-05Cancer Ag 19-9 [Units/volume] in Serum or Plasma18U/mL<=35 U/mLNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-10-05Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
2026-10-05Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
2026-10-05Albumin/Creatinine [Mass Ratio] in Urine12mg/g<=30 mg/gNormalS

Physical Exam

Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]

SystemFinding
GeneralThin, well; weight 51.8 kg; blood pressure 106/68, pulse 86
AbdomenHealed upper midline and right subcostal incision without hernia or redness; soft; mildly tender at the wound
EyesNo icterus
FeetMonofilament sensation and pulses normal; no lesions
ExtremitiesNo leg swelling
PsychiatricEngaged; planning her writing around the treatment days

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPresolvedconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolvedresolvedconfirmed K52.1S — Synthetic treatment effect; not a historical claim.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.
After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetesactiveconfirmed Z90.411S — Synthetic consequence of the synthetic operation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySurgical pathologyAfter resectionUp to dateypT2N1 (2 of 18 nodes), R0, perineural invasion, CAP tumor regression score 2
LaboratoryCA 19-9At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six monthsCompleted today18 U/mL, normal
LaboratoryBlood count with neutrophils and plateletsBefore chemotherapy after surgeryCompleted todayHemoglobin 10.6 g/dL, white cells 8.2, neutrophils 5.1, platelets 302
LaboratoryKidney and liver function, electrolytes and albuminBefore chemotherapy after surgeryCompleted todaySodium 137, potassium 4.3 mmol/L; creatinine 0.71 mg/dL, eGFR 116; ALT 22, AST 24, alkaline phosphatase 110 U/L, bilirubin 0.5 mg/dL; albumin 3.4 g/dL
ImagingBaseline CT after surgeryBefore chemotherapy after surgery or within three months of surgeryDueOrdered with the oncology team for before the third cycle after surgery; the CT before surgery showed no spread
Medication safetyVenous thromboembolism prophylaxisAfter surgery and during chemotherapyCompleted todayEnoxaparin for four weeks after surgery completed; apixaban 2.5 mg twice daily to restart with chemotherapy
Self-managementWeight, nutrition and enzyme replacementEach visitCompleted todayWeight 51.8 kg, 6.5 percent below the weight at diagnosis; pancrelipase increased; dietitian this week
LaboratoryGlucose and home readingsEach visit and before each cycleCompleted todayGlucose 156 mg/dL; home fasting 140 to 170 on 8 units of glargine
LaboratoryA1cEvery three months while treatment changesUp to date7.0% eight weeks ago; next in December, three months after that one
ExaminationDilated eye examination and urine albumin-to-creatinine ratioAt diagnosis of diabetes, then yearlyCompleted todayUrine albumin-to-creatinine ratio 12 mg/g today, normal, closing part of the deviation recorded at cycle 4. The dilated eye examination is booked for next week
ExaminationFoot examinationAt diagnosis of diabetes, then yearlyCompleted todayNormal sensation and pulses
ExaminationOxaliplatin neuropathy: symptoms and examinationAt each visit after oxaliplatinCompleted todayAlmost resolved
SurveyPain score and opioid reviewEach visitCompleted todayPain 2 out of 10 at the wound
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 7 and GAD-7 6
Self-managementSerious illness conversation and advance care planningAt diagnosis and at each change in treatmentCompleted todayReviewed with palliative care last week; to be recorded formally at the preventive visit

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Chemotherapy after surgery from next week. Dietitian and eye examination this week and next. Preventive visit in about two weeks. Call for fever of 38.0 °C or more, yellow eyes, low glucose readings, or worsening diarrhea. Next scheduled visit 2026-10-21: periodic adult preventive visit during chemotherapy after surgery. [S]